Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


José Ferreira Saraiva has a total of 82 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dinâmica de transmissão de arboviroses: integração entre vigilância entomológica e molecular de Aedes spp. e análise espacial em Macapá, Amapá

    by Fred Julio Costa Monteiro, José Ferreira Saraiva, Fábio Rodrigo Paixão Mourão, Heider Luan Carvalho Ferreira, Márcia Socorro Cavalcante Porcy, Marlúcia dos Santos Façanha, Dayse Swelen da Silva Ferreira, Allan Kardec Ribeiro Galardo, Raimundo Nonato Picanço Souto, Elizabeth Machado Barbosa, et al.

    A presente objetivou avaliar a infectividade das larvas e pupas de Ae. aegypti e Ae. albopictus coletadas durante os ciclos do Levantamento Rápido de Índices para Aedes aegypti (LIRAa) realizados em 2024 e 2025, integrando os achados entomológicos e laboratoriais à espacialização dos casos prováveis/confirmados de dengue, zika e febre de Chikungunya. Neste estudo foram realizados quatro ciclos de LIRAa, um no segundo semestre de 2024, dois no primeiro semestre de 2025 e outro no segundo semestre de 2025, dos quais dois destes foram classificados como baixo risco (Ciclo 03/2024 e 03/2025) e dois de médio risco (ciclo 01/2025 e 02/2025), com predominância de depósito lixo e pneus. Foram coletados 1.423 imaturos de Ae. aegypti e 543 de Ae. albopictus, originando 93 e 49 pools de até 20 espécimes, respectivamente. Todas as amostras foram testadas pela técnica de RT-PCR para detecção de RNA viral, não havendo amplificação de RNA viral em nenhuma das amostras testadas. Durante o estudo, foram registrados, 1.702 casos prováveis de dengue, 5 casos confirmados de zika e 40 de febre de Chikungunya. Destaca-se a dissonância entre os resultados obtidos do LIRAa e a epidemiologia dos agravos, especialmente nos ciclos considerados de baixo risco, mas com elevada incidência. A transmissão transovariana das arboviroses nos hospedeiros invertebrados não possui relevância epidemiológica para sustentar epidemia destas arboviroses. Por fim, devem ser adotadas ações de controle integrado de vetores de forma multissetorial, fundamentada nas ações rotineiras das equipes de saúde, saneamento básico, zeladoria urbana e educação em saúde.

  • Open Access

    Efficiency of four trap types and human landing catch in the sampling of Mansonia (Diptera, Culicidae) in Porto Velho, Rondônia, Brazil

    by Nercy Virginia Rabelo Furtado, José Ferreira Saraiva, Kaio Nabas Ribeiro, Noel Santos Fernandes Neto, Jéssica Fernanda Dos Santos Barroso, Cynara de Melo Rodovalho, Dario Pires Carvalho, Allan Kardec Ribeiro Galardo, José Bento Pereira Lima

    Entomological surveillance plays a crucial role in designing and implementing mosquito control measures. In this context, developing more effective collection strategies is essential to accurately estimate the entomological parameters necessary for effective control. In this study, we investigated the effectiveness of four traps: CDC light trap, MosqTent, BG-Sentinel, and SkeeterVac, compared to human landing catch (HLC) in the collection of Mansonia mosquitoes, known to cause discomfort to riverside populations along the Madeira River in the District of Jaci Paraná, Porto Velho, in Rondônia state, Brazil. Sampling was conducted, during three periods corresponding to two seasons, dry and rainy, over five consecutive days for each period. The captures using HLC and the installation of the traps took place on the grounds of five selected residences from 6 to 10 pm. Rotational exchanges between houses ensured that all traps and the HLC were used in each of the five residences, following a predetermined Latin square pattern. A total of 7,080 mosquitoes were collected, of which 90.5% belonged to the Mansonia genus, distributed in four species: Mansonia titillans (75.97%), Mansonia humeralis (18.91%), Mansonia amazonensis (1.90%), and Mansonia indubitans (1.37%). HLC captured the highest number of Mansonia mosquitoes (58.1%), followed by SkeeterVac (21.8%) and MosqTent (18.9%). CDC and BG-Sentinel showed a very low performance (0.92 and 0.23%, respectively). Although HLC performed better in capturing Mansonia, our results suggest that SkeeterVac and MosqTent can serve as valuable additional tools to entomological inventories or sentinels for detecting invasive species in areas with high epidemiological vulnerability, thereby providing evidence-based recommendations for improving mosquito control measures and entomological surveillance.


  • Open Access

    Aedes aegypti var. queenslandensis: the pale phenotype of Aedes aegypti L. has landed in Amapá

    by José Ferreira Saraiva, Dayse Swelen da Silva Ferreira, Felipe Greiner Amoras, Brenda Landrine Vilhena Nunes, Maria Luiza Cechim de Seixas Duarte, Fred Júlio Costa Monteiro, Ahana Maitra, Allan Kardec Ribeiro Galardo

    Background: Aedes aegypti var. queenslandensis, a pale form of Aedes aegypti, is widespread in Asia and adapted to urbanized and warm environments. Methods: Two BG-Sentinel traps with BG-Lure were deployed in an urban forest fragment between December 19 and 24, 2024, to monitor mosquito vectors. Results: A total of 191 specimens of Ae. aegypti var. queenslandensis were collected, marking the first record of this variety in Macapá, Amapá. Conclusions: This finding suggests that the population was introduced via maritime transport and highlights the need to strengthen entomological surveillance and assess potential insecticide resistance in vector control efforts in Macapá.


  • Open Access

    Molecular Identification of Mosquitoes (Diptera: Culicidae) Using COI Barcode and D2 Expansion of 28S Gene

    by Tatiane M. P. Oliveira, José F. Saraiva, Herculano da Silva, Maria Anice M. Sallum

    The purpose of this study is to improve the identification of Culicidae species from the Vale Ribeira region, São Paulo state, Brazil. Adults were collected in the municipalities of Cananeia and Pariquera-Açu and morphologically identified. Molecular analyses were performed on sequences of COI barcode and a fragment of the D2 expansion of the 28S ribosomal RNA gene generated from field collected mosquitoes. The analyses included species delimitation, phylogeny, and interspecific genetic distances using the Kimura 2-parameter model. Species included in the analyses were Aedes perventor, Aedes scapularis, Aedes serratus/Aedes nubilus, Aedes serratus s.s., Aedes terrens, Haemagogus capricornii, Haemagogus leucocelaenus, Haemagogus janthinomys, Kerteszia bellatrix, Kerteszia cruzii, Psorophora ferox, Psorophora forceps, Sabethes conditus, and Wyeomyia confusa. COI sequences from specimens collected at other localities were included in the analysis for comparison. Results of barcode RESL analysis showed that specimens of Ps. ferox and Hg. janthinomys split into three clusters for each species. Similarly, sequences of Ke. bellatrix and Ke. cruzii were recovered in two groups for each species. Distinct from other species included in analyses, Ps. ferox and Ps. forceps shared 100% similarity in the D2 fragment sequenced. Overall, the analysis of COI barcode sequences revealed the following key findings: (1) the presence of subclades within Hg. janthinomys, with its division into three groups suggests that this species may represent a species complex; (2) Ke. bellatrix from the Atlantic tropical rainforest shares 95.59% sequence similarity with a specimen from the type locality, indicating that specimens from Southeastern Brazil may belong to an unidentified species within the Ke. bellatrix complex; (3) Ke. cruzii also represents a species complex; and (4) D2 sequences successfully identified most species studied, apart from Ps. forceps and Ps. ferox.


  • Description of Trichophoromyia jariensis, a new species of phlebotomine sand fly (Diptera: Psychodidae) from the eastern Amazon

    by Keison S Cavalcante, Bruno L Rodrigues, Laura Posada-López, Taires Peniche, José F Saraiva, Allan Kardec R Galardo, Eunice A B Galati

    A new sand fly species, Trichophoromyia jariensis n. sp. Cavalcante, Rodrigues, & Galati, from the state of Amapá, Brazil, is described based on both male and female morphology and cytochrome c oxidase subunit I DNA barcodes. The DNA barcoding analysis clearly associated males and females of this new species.


  • Open Access

    Trends of Mansonia (Diptera, Culicidae, Mansoniini) in Porto Velho: Seasonal patterns and meteorological influences

    by José Ferreira Saraiva, Nercy Virginia Rabelo Furtado, Ahana Maitra, Dario P Carvalho, Allan Kardec Ribeiro Galardo, José Bento Pereira Lima

    Entomological research is vital for shaping strategies to control mosquito vectors. Its significance also reaches into environmental management, aiming to prevent inconveniences caused by non-vector mosquitoes like the Mansonia Blanchard, 1901 mosquito. In this study, we carried out a five-year (2019–2023) monitoring of these mosquitoes at ten sites in Porto Velho, Rondônia, using SkeeterVac SV3100 automatic traps positioned between the two hydroelectric complexes on the Madeira River. Throughout this period, we sampled 153,125 mosquitoes, of which the Mansonia genus accounted for 54% of the total, indicating its prevalence in the region. ARIMA analysis revealed seasonal patterns of Mansonia spp., highlighting periods of peak density. Notably, a significant decreasing trend in local abundance was observed from July 2021 (25th epidemiological week) until the end of the study. Wind speed was observed to be the most relevant meteorological factor influencing the abundance of Mansonia spp. especially in the Joana D’Arc settlement, although additional investigation is needed to comprehensively analyze other local events and gain a deeper understanding of the ecological patterns of this genus in the Amazon region.


  • Open Access

    Primeiro registro de Lutzomyia longipalpis (Lutz e Neiva, 1912) em Macapá, Amapá

    by Keison de Souza Cavalcante, Allan Kardec Ribeiro Galardo, José Ferreira Saraiva, Tatiane Alves Barbosa, Érika Oliveira Galeno, Marcio Claudio de Lima Nunes, Ana Paula Sales de Andrade Correa, Nayma da Silva Picanço, Fredy Galvis-Ovallos, Eunice Aparecida Bianchi Galati

    Lutzomyia longipalpis (Lutz & Neiva, 1912) constitutes the most epidemiologically relevant vector of visceral leishmaniasis (VL) in the New World. On October 25, 2023, the Macapá Center for Strategic Information in Health Surveillance registered a case of VL in the Km9 neighborhood, in Macapá. This study aimed to describe the Phlebotominae species in this area to assist the confirmation of the autochthony of the case. In total, 12 specimens were collected, of which five belonged to the Lutzomyia longipalpis species, confirming the presence of the VL agent vector and the possible autochthony of the transmission.


  • Open Access

    Seasonality and Biting Behavior ofMansonia(Diptera, Culicidae) in Rural Settlements Near Porto Velho, State of Rondônia, Brazil

    by Allan Kardec R Galardo, Andréa V Hijjar, Liliane Leite O Falcão, Dario P Carvalho, Kaio Augusto N Ribeiro, Guilherme A Silveira, Noel Fernandes S Neto, José F Saraiva

    Mansonia (Diptera: Culicidae) are known to cause discomfort to the local populations of Amazon. Considering the fact that the effective control of these mosquitoes can only be obtained by understanding their ecology and behavior, entomological monitoring becomes essential. In view of this, mosquitoes of the genus Mansonia were collected by human landing catches (HLC) from 2015 to 2019, in four locations of Porto Velho, Rondônia, Brazil. The collections were performed inside and outside the homes, once in every four months, uninterrupted for 24 hr. Human bite indices/hour was used to analyze the hourly activity of the species for different seasons and environment (indoor and outdoor). Moreover, nonparametric Mann–Whitney tests were conducted to indicate if there were differences between exophagic and endophagic behavior. The seasonality of Mansonia species was also analyzed. Overall, 96,766 specimens were collected over five years of sampling. Mansonia titillans (Walker) was found to be the most abundant species (76.9%). The highest percentage of mosquitoes was collected in February (48.4%), followed by October (39.6%) and June (12.0%). The biting activity of the two most abundant species showed peak host seeking activity/behavior during twilight and night, more perceptible in the outdoor environment (peridomiciliary). In general, seasonality showed a tendency towards a reduction in the abundance of Mansonia in the years after 2015. Our results will be essential in the formulation of effective control methodology for Mansonia in the studied area.


  • Open Access

    Anopheline species (Diptera: Culicidae) from the Maracá Ecological Station, Roraima State, Brazil

    by Vera Margarete Scarpassa, José Ferreira Saraiva

    Anopheline species were sampled in different ecotones at Maracá Ecological Station and in Cantá municipality, both in Roraima State, Brazil, in June 2016. Nine species were recorded. Six species belong to the subgenus Nyssorhynchus and three species to the subgenus Anopheles. The most abundant species collected were Anopheles triannulatus s.l., Anopheles nuneztovari s.l. and Anopheles oswaldoi species B. The remaining species had frequencies lower than 10%. While A. triannulatus s.l. was the most frequent and the most widely distributed species in the studied area, Anopheles darlingi Root, the main malaria vector in the Brazilian Amazon region, was captured in two different ecotones and in low frequency. Our findings suggest that the risk of malaria outbreaks at Maracá Ecological Station may be low. This study also describes the first record of Anopheles costai Fonseca & Ramos in Maracá Ecological Station, Roraima State, increasing the distribution range of this taxon.


  • Open Access

    Baricitinib plus Standard of Care for Hospitalised Adults with COVID-19 on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation: Results of a Randomised, Placebo-Controlled Trial

    by E. Wesley Ely, Athimalaipet V. Ramanan, Cynthia E. Kartman, Stephanie de Bono, Ran Liao, Maria Lucia B. Piruzeli, Jason D. Goldman, José Francisco Kerr Saraiva, Sujatro Chakladar, Vincent C. Marconi, et al.

    Background The oral, selective Janus kinase (JAK)1/JAK2 inhibitor baricitinib demonstrated efficacy in hospitalised adults with COVID-19. This study evaluates the efficacy and safety of baricitinib in critically ill adults with COVID-19 requiring invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO). Methods COV-BARRIER was a global, phase 3, randomised, double-blind, placebo-controlled trial in patients with confirmed SARS-CoV-2 infection (ClinicalTrials.gov NCT04421027). This addendum trial added a critically ill cohort not included in the main COV-BARRIER trial. Participants on baseline IMV/ECMO were randomly assigned 1:1 to baricitinib 4-mg (n=51) or placebo (n=50) for up to 14 days in combination with standard of care (SOC). Prespecified endpoints included all-cause mortality through days 28 and 60, and number of ventilator-free days, duration of hospitalisation, and time to recovery through day 28. Efficacy and safety analyses included the intent-to-treat and safety populations, respectively. Findings SOC included baseline systemic corticosteroid use in 86% of participants. Treatment with baricitinib significantly reduced 28-day all-cause mortality compared to placebo (39·2% vs 58·0%; hazard ratio [HR]=0·54 [95%CI 0·31–0·96]; p=0·030). One additional death was prevented for every six baricitinib-treated participants. Significant reduction in 60-day mortality was also observed (45·1% vs 62·0%; HR=0·56 [95%CI 0·33–0·97]; p=0·027). Baricitinib-treated participants showed numerically more ventilator-free days (8.1 vs 5.5 days, p=0.21) and spent over 2 days less in the hospital than placebo-treated participants (23·7 vs 26·1 days, p=0·050). The rates of infections, blood clots, and adverse cardiovascular events were similar between treatment arms. Interpretation In critically ill patients with COVID-19 already receiving IMV/ECMO, treatment with baricitinib as compared to placebo (in combination with SOC, including corticosteroids) showed mortality HR of 0·56, corresponding to a 44% relative reduction at 60 days. This is consistent with the mortality reduction observed in less severely ill hospitalised primary COV-BARRIER study population. Funding Eli Lilly and Company. Evidence before this study We evaluated current and prior studies assessing the efficacy and safety of interventions in patients requiring invasive mechanical ventilation (IMV) and searched current PubMed using the terms “COVID-19”, “SARS-CoV-2”, “treatment”, “critical illness”, “invasive mechanical ventilation”, “baricitinib”, and “JAK inhibitor” for articles in English, published until December 1, 2020, regardless of article type. We also reviewed the NIH and IDSA COVID-19 guidelines and reviewed similar terms on clinicaltrials.gov. When the critical illness addendum study to COV-BARRIER study was designed, there was only one open-label study of dexamethasone showing mortality benefit in hospitalised patients with COVID-19 requiring IMV. Small studies of interleukin-6 inhibitors had shown no effect and larger trials were underway. Guidelines recommended use of dexamethasone with or without remdesivir and recommended against the use of interleukin-6 inhibitors, except in a clinical trial. Overall, there were no reported double-blind, placebo-controlled phase 3 trials which included corticosteroids as part of SOC investigating the efficacy and safety of novel treatments in the NIAID-OS 7 population. Baricitinib’s mechanism of action as a JAK1 and JAK2 inhibitor was identified as a potential intervention for the treatment of COVID-19 given its known anti-cytokine properties and potential antiviral mechanism for targeting host proteins mediating viral endocytosis Data from the NIAID sponsored ACTT-2 trial showed that baricitinib when added to remdesivir improved time to recovery and other outcomes including mortality compared to placebo plus remdesivir. A numerically larger proportion of participants who received baricitinib plus remdesivir showed an improvement in ordinal scale compared to those who received placebo plus remdesivir at day 15 in participants requiring IMV (NIAID-OS score of 7) at baseline. We designed COV-BARRIER, a phase 3, global, double-blind, randomised, placebo-controlled trial, to evaluate the efficacy and safety of baricitinib in combination with SOC (including corticosteroids) for the treatment of hospitalised adults with COVID-19 who did not require mechanical ventilation (i.e., NIAID-OS 4-6). A significant reduction in mortality was found after 28 days between baricitinib and placebo (HR 0·57, corresponding to a 43% relative reduction, p=0·0018); one additional death was prevented per 20 baricitinib-treated participants. In the more severely ill NIAID-OS 6 subgroup, one additional death was prevented per nine baricitinib-treated participants (HR 0·52, corresponding to a 48% relative reduction, p=0·0065). We therefore implemented an addendum to the COV-BARRIER trial to evaluate the benefit/risk of baricitinib in the critically ill NIAID-OS 7 population and considered the sample size of 100 participants sufficient for this trial. Added value of this study This was the first phase 3 study to evaluate baricitinib in addition to the current standard of care (SOC), including antivirals, anticoagulants, and corticosteroids, in patients who were receiving IMV or extracorporeal membrane oxygenation at enrolment. This was a multinational, randomised, double-blind, placebo-controlled trial in regions with high COVID-19 hospitalisation rates. Treatment with baricitinib reduced 28-day all-cause mortality compared to placebo (HR 0·54, 95% CI 0·31–0·96; nominal p=0·030), corresponding to a 46% relative reduction, and significantly reduced 60-day all-cause mortality (HR 0·56, 95% CI 0·33–0·97; p=0·027); overall, one additional death was prevented per six baricitinib-treated participants. Numerical improvements in endpoints such as number of ventilator-free days, duration of hospitalisation, and time to recovery were demonstrated. The frequency of serious adverse events, serious infections, and venous thromboembolic events was similar between baricitinib and placebo, respectively. The COV-BARRIER study overall trial results plus these COV-BARRIER addendum study data in mechanically ventilated and ECMO patients provide important information in context of other large, phase 3 randomised trials in participants with invasive mechanical ventilation at baseline. The RECOVERY study reported mortality of 29·3% following treatment with dexamethasone compared to 41·4% for usual care (rate ratio of 0·64, corresponding to a 36% relative reduction) and 49% mortality in participants who received tocilizumab compared to 51% for usual care (rate ratio of 0.93, corresponding to a 7% relative reduction). The ACTT-2 study reported 28-day mortality of 23·1% and 22·6% in the baricitinib plus remdesivir and placebo plus remdesivir groups, respectively, in this critically ill patient population; however, the primary outcome of this trial was time to recovery, so was not powered to detect a change in mortality. Implications of all the available evidence In this phase 3 addendum trial, baricitinib given in addition to SOC (which predominantly included corticosteroids) had a significant effect on mortality reduction by 28 days in critically ill patients, an effect which was maintained by 60 days. These data were comparable with those seen in the COV-BARRIER primary study population of hospitalised patients, but which excluded patients who required IMV or extracorporeal membrane oxygenation at enrolment. These findings suggest that baricitinib has synergistic effects to other SOC treatment modalities including remdesivir and dexamethasone. Based on the available evidence, baricitinib is a novel treatment option to decrease mortality in hospitalised, critically ill patients with COVID-19 even when started late in the disease process after steroids, mechanical ventilation, and ECMO have already been implemented.